Skip to main content
European Medicines Agency's logo Go to homepage

Main navigation

  • Medicines
    • Find medicine
    • Therapeutic areas: latest updates
    • Download medicine data
    • What we publish on medicines and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Medical devices
    • Herbal products
  • Veterinary regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    • Overview
    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    • Overview
    • News
    • Events
    • What's new
    • Committee highlights
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    • Overview
    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    • Overview
    • What we do
    • Who we are
    • How we work
    • Fees
    • Support to SMEs
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • Contacts
  1. Home
  2. Medicines
  3. Aivlosin - withdrawal of application for variation to marketing authorisation

Aivlosin - withdrawal of application for variation to marketing authorisation

Application withdrawn

The application for a change to this medicine's authorisation has been withdrawn.

tylvalosin
Post-authorisationVeterinary

Page contents

  • Overview
  • Key facts
  • Documents
  • Related information on withdrawals
  • News on Aivlosin
  • More information on Aivlosin

Overview

The applicant ECO Animal Health Europe Limited submitted on 31 January 2020 an application for an extension to the marketing authorisation for Aivlosin to the European Medicines Agency (The Agency) in accordance with Article 19 of Commission Regulation (EC) No 1234/2008 and Annex I thereof.

Aivlosin (active substance: tylvalosin), is a macrolide antimicrobial and was first authorised for use in pigs in the Union on 9 September 2004. The product is currently authorised for use in pigs, chickens and turkeys for various antibacterial indications, and is available as premix for medicated feed, oral powder and granules for use in drinking water.

This extension application is for a new target species, chickens, for the 42.5 mg/g premix for medicated feed presentation (currently only authorised for use in pigs). At the time of submission, the applicant applied for the following indication: “Treatment and metaphylaxis of respiratory disease associated with Mycoplasma gallisepticum in chickens.”

The dossier has been submitted in accordance with Article 19 of Commission Regulation (EC) 1234/2008 and Annex I thereof (extensions).

On 17 March 2021, ECO Animal Health withdrew the application at day 181 of the procedure. In its letter notifying the Agency of the withdrawal of application, the applicant stated that the reason for the withdrawal was based on a commercial decision.

Key facts

Name of medicine
Aivlosin
EMA product number
EMEA/V/C/000083
Active substance
tylvalosin
International non-proprietary name (INN) or common name
tylvalosin
Date of withdrawal
17/03/2021

Documents

Withdrawal assessment report for Aivlosin

AdoptedReference Number: EMA/174508/2021

English (EN) (464.52 KB - PDF)

First published: 07/12/2021
View

Withdrawal letter: Aivlosin

English (EN) (18.23 KB - PDF)

First published: 07/12/2021
View

Related information on withdrawals

The question-and-answer (Q&A) document provides a summary of the CVMP's evaluation of the application at the time of the withdrawal, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CVMP's evaluation is completed ('day 90').

News on Aivlosin

Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 12-13 March 2024
18/03/2024
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 13-14 February 2024
16/02/2024
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 16-18 March 2021
19/03/2021
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 16-17 February 2021
19/02/2021
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 16-17 February 2021
19/02/2021
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 14-16 July 2020
17/07/2020
Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 18-20 May 2020
25/05/2020
Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 13-15 February 2018
16/02/2018
Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 10-12 April 2017
18/04/2017
Committee for Medicinal Products for Veterinary Use (CVMP) meeting 6-8 December 2016
09/12/2016
Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 19-21 April 2016
22/04/2016
Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 16-18 February 2016
19/02/2016
Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 8-10 September 2015
11/09/2015
Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 10-12 February 2015
13/02/2015
Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 7-9 October 2014
10/10/2014
Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 8-10 July 2014
11/07/2014
Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 11-13 March 2014
14/03/2014
Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 8-10 October 2013
11/10/2013
Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 9-11 April 2013
12/04/2013
Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 6-8 March 2012
09/03/2012
Committee for Medicinal Products for Veterinary Use (CVMP): Meeting of 9-11 February 2010
12/02/2010

More information on Aivlosin

  • Aivlosin
This page was last updated on 07/12/2021

Share this page

Back to top

Product emergency hotline

OUTSIDE WORKING HOURS

About us
What we do
Careers
Committees & working parties
Regulatory network
European experts
Languages
Frequently asked questions
Glossaries
About this website
Cookies
Website data protection notice
Data protection at EMA
Search tips
Access to documents
Contacts
Send a question
EMA Service Desk (system support)
Services and databases

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us
Postal address and deliveries
Business hours and holidays

  • RSS Feed
  • Bluesky
  • YouTube
  • LinkedIn
© 1995 - 2025 European Medicines Agency
European Union agencies network
An agency of the European Union